Not sure if you will be alive until then due to EBOLA attacking you.
We are planning to give this medicine a try and results seems to be good not just for EBOLA, but for cancer too.
I see the PT was raised to $9 earlier by Roth Capital. With this release we will see the PT to raise again from $9? I know with just one firm giving a PT it might not boost the investor confidence, but I HOPE additional analysts will get on it soon.
Anyone see any PT update on PPHM?
where do you see the PT?
After rising 47 percent Friday on positive trial results, shares of Peregrine Pharmaceuticals (NASDAQ: PPHM) are tacking on another 9 percent in pre-open trading Monday after Roth Capital boosted its price target from $5 to $9. The firm also reiterated its Buy rating.
Just got long yesterday at the end of the day when it turned -ve. But with new CEO there could be lot of changes, might be +ve or -ve only time will decide and I am not sure if I would still be here. But for now the new CEO has a history of success and turning around company from loss to profit. and JCP is a brand that is too big to fail with this CEO as the market is turning better.
All the best to longs!!.
Why is that we don't hear a partnership or someone showing interest even with approval from Germany and UK? Why does the street manipulate their statements? Why did GS, Morgan Stanley, BlackRock and Vanguard own this stock?
I a long, but I am trying to think like a short to see why this stock is hit so badly recently even with good news. It does not make any sense.
nice..response. But seems like AF is AF (he created a repo by his false statements which creates advantages for shorts to short it initially and then big hedge funds to buy low. Only the retail investors/day traders will need to suffer.
right, I do think that this is cheap at these prices, but look at the market, everything is down. Even if this turns green on one/few days, this will be down again and will never even see this bottom price.
Its blood all over and small companies are hit the hardest.
You are right sproker, but the problem is with day traders and few who added more on margin accounts. Whatever you say, they are not going to listen to you as they might have received a margin call, even if they don't intend to sell, brokerage firms will sell their shares forcefully.
US Company Awarded UK's First "Promising Innovative Medicine" Designation. But getting a PIM is not straightforward. The company has to convince MHRA that the condition is life threatening or seriously debilitating with a high unmet need. They also have to convince them that the product will offer a major advantage to methods already used in the UK, and that any adverse effects are likely to be outweighed by the benefits.
Germany has granted Northwest Biotherapeutics Inc special permission to sell its experimental brain cancer drug in the country,also have the right to seek renewal of the exemption after five years. It is the first hospital exemption in Germany for a product never previously on the market.
At least 3,000 new cases of GBM are seen in Germany each year, another 4,000 cases of lower-grade brain tumors that will also be eligible for treatment with DCVax-L
Northwest has attracted the interest of large institutional players such as Goldman Sachs, while some investors have taken short positions in the stock, at around 9 percent of its shares as of February 14.
independent data safety monitoring board had recommended the trial continue, based on its safety review
Northwest Biotherapeutics is pushing ahead following two high-profile disappointments of dendritic cell-based therapies from ImmunoCellular Therapeutics Ltd and Dendreon Corp
Industry analysts say DCVax-L could potentially be worth more than a billion dollars in annual sales if it eventually wins full marketing approval in Europe and the United States.
Northwest Biotherapeutics expects to report complete data from its formal late-stage trial of DCVax-L in 2015
More to come.....
I agree, but longs and short play with your emotions and then grab your $$. The truth of stock market.
One more thing: The DCVax efficacy interim analysis AWOL for months now may finally come out of hiding now that the financing is done. The company no longer has to worry about the stock tanking.